On-Demand Webinar

Best Practices: Nucleic Acid Removal from Vaccine Process

Duration: 1 Hour
Speaker: Frank Appel, Senior Manager Europe Vaccines Segments, MilliporeSigma

Abstract: The production of viral vaccines at commercial scale requires large quantities of viruses as an antigenic source. There are different production platforms suitable for viral replication - mammalian, avian and insect cells. Host cell residuals in the final product - nucleic acid in particular - create a significant concern due to a potential transfer and integration into the living cell’s genetic material, potentially leading to various harmful effects including cancer. Health authorities and regulatory bodies continue to increase safety standards for the manufacturing products providing stringent guidelines on removal of residual nucleic acid from vaccine processes. Several physicochemical methods exist to reduce nucleic acid during the manufacturing processes. Please join us to learn more about recent advances in efficiently removing nucleic acids from vaccine processes. The webinar will highlight diverse methods such as enzymatic degradation with endonucleases or ultrafiltration/diafiltration and chromatography to easily reduce nucleic acid contaminants from your vaccine manufacturing process.

Register to Watch Now